Tissue transglutaminase is a ubiquitous and multifunctional protein that contributes to several processes such as apoptosis/survival, efferocytosis, inflammation and tissue repairing under physiological and pathological conditions. Several activities can be associated with well-established functional domains; in addition, four RNA alternative splice variants have been described, characterized by sequence divergences and residues deletion at the C-terminal domains. Tissue transglutaminase is recognized as the central player in the physiopathology of coeliac disease (CD) mainly through calcium-dependent enzymatic activities. It can be hypothesized that differential regulation of tissue transglutaminase splice variants expression in persons with CD contributes to pathology by altering the protein functionality. We characterized the expression pattern of RNA alternative splice variants by RT-PCR in peripheral cells from patients with CD under free gluten diet adhesion; we considered inflammatory parameters and specific antibodies as markers of the stage of disease. We found significant higher expression of both the full length and the shortest C-truncated splice variants in leucocytes from patients with CD in comparison with healthy individuals. As tissue transglutaminase expression and canonical enzymatic activity are linked to inflammation, we studied the RNA expression of inflammatory cytokines in peripheral leucocytes of persons with CD in relation with splice variants expression; interestingly, we found that recently diagnosed patients showed significant correlation between both the full length and the shortest alternative spliced variants with IL-1 expression. Our results points that regulation of alternative splicing of tissue transglutaminase could account for the complex physiopathology of CD.
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| INTRODUCTION
Transglutaminase type 2 (TG2) is a multifunctional and ubiquitous protein primarily involved in calcium-dependent post-translational modification of proteins. TG2 catalyses the cross-linking of proteins by the formation of isopeptide bonds between c-carboxamide group of glutamine and e-amino group of lysine (TGase activity).
1 TG2 also contributes to the protein aminylation 2 and deamidation of glutamine residues. 3 Independently of this calcium-dependent canonical activity, TG2 acts as a G-protein, participate in signal transduction and has adhesive functions. Through these complex activities, TG2 contributes to several physiological processes such apoptosis/survival, efferocytosis, inflammation and tissue repairing. 4 These multiple functions can be associated with the structure of TG2 (687aa) which comprise four domains ( Figure 1 ): N-terminal b-sandwich (1-139 aa) that contain integrin and fibronectin-binding sites; the central domain (147-460aa) containing the catalytic core for TGase activity and two C-terminal b-barrels that include a phospholipase C-binding sequence. 5 Residues of the core and b-barrels are involved in GTP/GDP binding. 6 Crystallographic data
show that an open conformation is associated with a calcium-dependent TGase activity while a closed conformation binds GTP and inhibits transamidating activity. [6] [7] [8] In addition, the TG2 homotypic associations through C-terminal residues would be involved in different inter-and intra-cross-linking regulatory activities. 9 The expression of different TG2 splice variants could contribute to the complex picture of this protein biology; in addition to the constitutively spliced full-length TG2 transcript, 10 four alternative spliced forms of human TG2 have been reported. They are characterized by C-terminal truncated sequences at different extent and divergences in comparison with full-length TG2 transcript ( Figure 1 ). TGM2_v4b. 14 The role of TG2 variants in normal cellular function and pathological conditions has been suggested. 15 It is considered that modifications at the C-terminal region might display altered catalytic and signal transduction properties according to structure-function correlation. The increased TG2 expression and TGase activity dysregulation is a common feature of several diseases; 16, 17 particularly, it is recognized as the central player molecule in the pathogenesis of coeliac disease (CD). 18 TG2 expression and activity is increased in the small intestine of patients with active disease; 19 in addition, extradigestive TG2 dysfunction can contribute to extradigestive disorders. 20, 21 The inflammatory status of CD can be systemically reflected by the increase in various serological parameters; after long-term adhesion to gluten-free diet (GFD), these inflammatory parameters and specific serology declines in line with gradual gut mucosal recovery indicating that gluten triggers the disease. 22, 23 TG2 is expressed in mononuclear cells that persist in chronically inflamed tissues such as monocytes/macrophages and polymorphonuclear cells characteristic of acute inflammation. Macrophages are main players in inflammation and tissue damage; both inflammatory and regulatory cytokines could induce TG2 expression and activity in these cells with different outcomes; both classic and alternative macrophage phenotypes have been associated with TG2 upregulation. [24] [25] [26] Up to now, TG2 variants expression in human leucocyte populations has not been explored; it remains possible that expression pattern of alternative TG2 molecules in persons with CD contribute to its dysregulation as this protein is key in inflammation and autoimmune response elicited by patients. To explore this issue, in this work, we characterize TG2 mRNA variants profile in leucocyte populations in health condition and in different stages of CD.
| MATERIAL AND METHODS

| Study group
We studied a group of 17 individuals (16 F and 1 M), median age 40 (range 21-70) with confirmed CD and a control group integrated by 9 healthy individuals (6 F and 4 M), median age 30 years (range 22-55). All patients had small bowel biopsy-proven CD and were adhered to a GFD since diagnosis. For analysis purpose, individuals with CD were grouped according to time since diagnosis confirmation and concomitant adhesion to GFD. Recently CD-diagnosed patients (group I) included those under GFD up to 5 months ago (n = 10 F; median age 48 years, range 27-70) and individuals with long-term GFD compliance since diagnosis integrate group II (6 F and 1 M, median age 33 (range 21-57).
Persons with CD were recruited from the Uruguayan Coeliac Association (ACELU); the participation of voluntary donors was in accordance with the ethical standards of the local human investigation ethical committee (Faculty of Chemistry, Universidad de la Rep ublica; N°101900-000371-12).
| Blood samples
Venous blood samples (15-20 mL) were collected from voluntary donors with confirmed diagnoses of CD and healthy individuals in tubes containing EDTA. Samples were immediately used for fractions obtention: total white blood cells (WBC), mononuclear cells (PBMC) and polymorphonuclear cells (PMN). Additionally, 3 mL of blood was collected to separate serum, and conserved at À20°u ntil use. Informed consent for blood sampling was previously obtained from all donors according to Ethical Committee.
| Serological profile
Levels of tissue transglutaminase-specific IgA and IgG antibodies were determined by ELISA using Quanta Lite_ h-tTG IgA and Quanta Lite_ h-tTG IgG ELISA; the antigliadin IgG/IgA-specific reactivity was analysed with deamidated gliadin synthetic peptides (Quanta Lite DGP screen; Inova). In all cases, we proceeded according to the manufacturer's instructions (INOVA Diagnostics, Inc., San Diego, CA, USA). The presence of IL-1 and IL-6 in serum samples was analysed by Standard ABTS ELISA Development Kits (PeproTech, Rocky Hill, USA), with quantification detections being 6 and 8 pg/ mL, respectively.
| Leucocyte fractions purification
PBMC and granulocytes were obtained by density gradient centrifugation onto Hystopaque 1077 (Sigma, St. Louis, USA) by standard method. Blood samples were processed immediately after extraction. Briefly, 20 mL of blood half diluted in isotonic phosphate buffered saline solution was layered and centrifuged at 400 g for 30 minutes at room temperature. Granulocytes were recovered from the pellet and erythrocytes lysed with EL buffer, QIAamp RNA blood Mini kit (Qiagen, Hilden, Germany). PBMC were recovered from the interface. Freshly isolated PBMC were immediately used for monocytes separation by plastic adherence as previously described. 27 
| RNA isolation and cDNA synthesis
Total RNA from whole blood or leucocytes fractions was isolated using QIAamp RNA blood Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The quantity and quality of RNA was assessed spectrophotometrically by NanoDrop 8000 (Thermo Scientific, Wilmington, DE, USA) (typical range 0.1-0.8 lg/lL RNA). Total RNA (1 lg) was reverse transcribed with random primers (SBS Genetech Co, Beijing, China) using M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA, USA), at 37°C for 60 minutes according to the manufacturer's instructions.
We tested amplification of sequences of interest from random samples with and without DNAsaI (Fermentas, Burlington, Canada), and with and without M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA, USA), discarding the possibility of amplification from gDNA.
| Real-time PCR
Real-time PCR was used to relative quantitation of TG2 variants and proinflammatory cytokines IL-1b and IL-6, respect to b-actin as housekeeping gene employing Maxima SYBR Green/ROX qPCR Master Mix (2X) (Thermo Scientific, Pittsburgh, PA). Oligonucleotide primers for TGM2_v1, _v2, IL-1b, IL-6 and b-actin were designed using Primer Express Software (Applied Biosystems, Foster City, California, USA): 28 we tested the primer sequences against each transcript sequence, ruling out cross-amplification of different variants. Real-time PCR reactions were performed in a Corbett Rotor-GeneTM 6000 rotary analyzer (initial denaturation: 95°C, 5 minutes; followed by 40 cycles: 95°C, 15 seconds; 60°C, 60 seconds). For all transcripts studied, a ramp temperature from 95 to 60°C was used to generate the melting curves, which were used to check the homogeneity of the amplified transcripts. A no-template control was included to rule out contamination. Relative quantifications were conducted by the 2 ÀDDCt method (fold increase = 2
ÀDDCt
, where DDCt = DCt sample À DCt reference, and DCt = Ct of gene of interest À Ct of houskeeping gene); 29 or comparison of DCt. All primers showed PCR efficiency >98%.
| Statistics
Mann-Whitney test was applied to compare data from different study groups. Friedman and Dunn's multiple comparison test were used for comparison of paired samples. The Pearson's test was used to analyse the correlation of data. Significance was indicated as: *P ≤ .05, **P ≤ .01, ***P ≤ .001, ****P ≤ .0001). GraphPadPrism 6 was used for analysis.
ARBILDI ET AL. In an attempt to evaluate whether the regulation of variant splicing could be modified during the course of CD, we studied the pattern of TG2 isoform mRNA expression in peripheral leucocytes from the whole group of patients with CD in comparison with healthy individuals. As it is depicted in Figure 2A , the pattern of TG2 variants expression in CD patients parallels that observed with leucocytes obtained from healthy individuals, as TGM2_v1 and TGM2_v2 were the most prominently variants expressed in both groups; TGM2_v1 was significantly higher expressed than TGM2_v3, TGM2_v4a and TGM2_v4b (P < .0001). Interestingly, the expression of TGM2_v1 significantly correlated with the expression of TGM2_v2 and TGM2_v3 in the whole group of patients (P = .0014, Pearson r = .7264 and P = .006, Pearson r = .6542 respectively) but not in the control group. Coeliac disease is a chronic disease characterized by an inflammatory lesion in the small intestine; it is considered that no less than 6 months of gluten avoidance is required to heal the intestinal damage. 30 All persons with CD in this work claimed to be adhered to a GFD since time of diagnosis; to categorize patients according to disease stage, we considered GFD period and different patterns of serological reactivity were observed accordingly ( Table 1) . Nine of ten patients recently diagnosed, with less than 6 months under GFD (group I) exhibited significant levels of specific antibodies against TG2 and/or gliadin. As it is expected, patients with long-term disease, with more than 2 years since diagnosis (group II) had no detectable levels of specific serum antibodies. Taking into account the clinical stage of disease, the mRNA expression of the full-length variant TGM2_v1 and the shortest transcript TGM2_v3 were similar between these groups and significantly higher (P < .01) in comparison with healthy individuals ( Figure 2B and C, respectively).
| TG2 variants mRNA expression in leucocyte subsets from persons with CD and healthy individuals
To further study the expression of TGM2 variants in leucocyte subsets with different contribution to CD pathology, we compared the TGM2 variants expression in purified monocytes, PMN cells and lymphocytes from persons with CD and healthy donors. We found substantial expression of mRNA coding for all TGM2 isoforms at variable levels according to the studied cell population. Remarkably, we show a wider range of expression among healthy and individuals with CD for TG2 variants in monocytes. Globally, the results show a similar pattern in patients and healthy individuals; as it is described in Figure 3 , the full-length variant TGM2_v1 showed the most prominent expression in all leucocyte populations, with significant higher expression than TGM2_v3, TGM2_v4a and TGM2_v4b. The expression level of TGM2_v1 and TGM2_v2 was similar in all cases, except for lymphocytes from patients with CD, which expressed significant higher expression of TGM2_v1. Nevertheless, no significant differences were observed regarding the expression of each TGM2 variant, between healthy and individuals with CD among all cell subsets.
| TG2 variants mRNA expression and inflammatory condition in persons with CD
The immune-mediated inflammation associated with untreated CD normalizes after long-term GFD in most patients. The stage of the disease can be reflected by specific serology and several inflammatory markers. 22 Although untreated patients are not included in our study, significant differences were observed among treated patients with CD, according to the time of GFD adherence. The level of serum IL-1 was significantly higher in the group of patients recently diagnosed compared with control group (P = .029); in contrast, the group of patients with longterm disease and control group exhibited similar levels of serum IL-1 (Table 1) . Then, we studied whether the inflammatory condition was also reflected in the mRNA expression of IL-1 and IL-6 in leucocytes. Our results show that patients with recently diagnosed CD had higher expression of IL-1 and IL-6 mRNA in comparison with control group, although the differences were not statistically significant ( Figure 4) . As TG2 overexpression can be associated with inflammatory conditions, we next analysed if the expression of the full-length transcript TGM2_v1 correlated with any IL-1 or IL-6 mRNA in the WBC obtained from persons with CD as these peripheral leucocytes can migrate into tissues and contribute to local inflammation. Our results show significant correlation between the expression of full-length TGM2_v1 as well as truncated TMG2_v2 variants with IL-6 mRNA expression in leucocytes from patients with CD (Pearson r = .5446; P < .0292 and r = .5507; P < .027 respectively; n = 10).
In addition, only the group of patients with recently diagnosed CD showed significant correlation between IL-1 mRNA expression with canonical TGM2_v1 and alternative spliced TGM2_v3 in peripheral WBC (Pearson r = .8091 and P < .015 and r = .7282 and P < .0405, respectively; n = 8). In line with these results, the group of patients with recently diagnosed CD exhibited significant higher levels of IL-1 in serum (Table 1) , although the source of this cytokine was not determined. In contrast, no significant correlation of the expression of inflammatory cytokines with any TGM2 splice variants was observed in cells from healthy individuals.
| DISCUSSION
The role of several TG2 spliced variants in biological processes in healthy and pathological conditions has been proposed by several authors, but their role in vivo is still unknown. 15 A systematical study about the expression of all TGM2 spliced variants in normal solid tissues was described; 11 in this work, the authors found variable contributions of all variants depending on tissue, with an overall predominance of the full-length TGM2_v1 and significant correlation among their expression. Nevertheless, a comprehensive study of the basal expression TGM2 variants in white blood cells was lacking. Thus, our first aim was to contribute to this knowledge by studying all TGM2 variants expression in leucocyte populations isolated from blood of healthy individuals. We found detectable mRNA expression of all TGM2 variants in samples from most individuals; in leucocyte fractions, TGM2_v1 was significantly more expressed than TGM2_v3, TGM2_v4a and TGM2_v4b while TGM2_v2 was expressed in similar levels than full-length transcript.
Globally, these results are in line with the original report that characterized TGM2_v4a and TGM2_v4b as the authors found about 4-5-fold expression of the full-length mRNA transcript in the mononuclear cell fraction.
14 In present work, we further dissect the analysis of mononuclear cells by purifying monocytes and lymphocytes. Differences between expression pattern of TGM2_v4a and TGM2_v4b in both populations merit further study on the basis of TG2 relevance in monocytes/macrophage functions. 31 Regarding expression of TGM2_variants in PMN cells, Lai et al 14 also found higher levels of TGM2_v1 in comparison with TGM2_v4b; in contrast to our data, they reported double level of TGM2_4a in PMN cells in comparison with TGM2_v1. The study of the association between TGM2 alternative splicing and pathological conditions is limited to neoplasic and neurodegenerative conditions. 11, 15 In particular, the link between TG2 and inflammation is widely known because the TG2 promoter has response elements for proinflammatory cytokines (IL-6, IL-1b, TNF-a) and NF-jB. [32] [33] [34] Besides, TG2 can promote sustained inflammation through NF-jB pathway by cross-linking the inhibitor factor I-jB 35, 36 and TG2 might contribute to inflammatory pathology perpetuation through this amplificatory loop. TG2 plays a central role in the pathogenesis of CD through the generation by TGase activity of neoepitopes of gluten that are efficiently presented by APC in the gut compartment. This is the main step in the inflammatory pathogenic cascade that leads to the gut lesion. 23 In addition, the extradigestive disorders are frequently observed in patients with CD and the aberrant expression and/or function of TG2 can also be implicated. 21 The white blood immune cells colonize peripheral tissues and play several functions that are regulated by TG2, such as repairing, inflammation and homeostasis. Taken together, we hypothesize that the dysregulation of TG2 activity through the regulation of alternative processing of the TGM2 transcript could contribute to intestinal and extradigestive disorders in CD.
As a first approach to explore this issue, we analysed the expression of mRNA TGM2 transcription variants in peripheral leucocytes of treated patients with CD because these cells can ultimately migrate to inflamed tissues and contribute to damage perpetuation in different compartments. In particular, the role of TG2 in monocyte/macrophage function in homeostasis and inflammatory conditions is remarkable. 31 In addition to classical inflammatory cells, increased lymphocytic infiltration is a hallmark of coeliac lesion; 37 thus, we aimed to study its expression in different leucocyte populations. Our results show that treated patients with CD have enhanced expression of TGM2_v1 and TGM2_v3 independently of the stage of disease; nevertheless, the significant correlation observed between the expression of both splice variants with the inflammatory status of the patients suggests an involvement of the TGM2 alternative splicing regulation in this pathology. In line with these results, we recently reported the upregulation of alternative spliced variants in another autoimmune and inflammatory condition; TGM2_v3 was induced by anti-b2 glycoprotein antibodies in macrophage-like differentiated THP-1 cells in parallel with an increased IL-1 and IL-6 production. These results are in accordance with the regulatory loop between TG2 and inflammation, but the consequences on cell function are still unknown. 38 The link between expression of an alternative spliced variant and dysregulation of TGase activity was reported in proinflammatory cytokines treated rat astrocytes. 39 In F I G U R E 4 Inflammatory cytokines in whole blood leucocytes. Relative expression of RNA transcript for IL-1 (A) and IL-6 (B) in whole blood leucocytes isolated from patients with recently diagnosed CD (group I), patients with long-term CD (group II) and healthy individuals (control group). The box plots show the medians (horizontal lines), range (whiskers) and individual values (points). The differences with respect to control group are indicated with asterisks addition, elevated expression and higher cross-linking activity of the most widely studied short variant (TGM2_v2) was reported in the brain of patients with Alzheimer disease, concomitantly with the formation of characteristic insoluble aggregates and neuronal death. 40, 41 Nevertheless, no information is available about functional properties of the shortest isoform TGM2_v3, initially described in an erythroleukemic cell line. 13 The lack of 338 residues and divergent sequence in the C-terminal region could considerably affect enzymatic and signal transduction functions. According to a recent study about spatial conformation of TGM2_v2, 42 C-terminal truncation would result in a protein with an open conformation, lacking GTP-binding sites and proapoptotic properties in NIH3T3 transfected cells; thus, an open conformation could also be speculated for TGM3_v3 although this issue warrants further investigation. Unfortunately, the evidence of TG2 C-truncated variants in primary cells at the protein level and the impact on cell function is still poorly studied. In relation with human leucocytes, the presence of the protein corresponding to the short variant TGM2_v4a was detected by immunoblot in peripheral mononuclear cells.
14 Besides, after retinoic acid treatment, short TG2 molecules were detected in erythroleukemia cells. 43 These data argue in favour of the expression of truncated TG2 molecules in white blood cells. Our results point that TG2 alternative splicing could account for the complex CD physiopathology in patients with CD. The functional consequences of the increased expression of the C-terminal truncated TGM2_v3 variant is under investigation in cells that contribute to aberrant control of inflammation and homeostatic mechanisms in other peripheral tissues often affected in CD.
